ESG Report 2021

Drug innovation and medical accessibility continue to receive widespread attention from the global pharmaceutical and intellectual property fields, and are related to the development of public health and the balanced development of pharmaceutical intellectual property rights. In order to enhance the Group's innovation capacity and competitiveness on the market, The United Laboratories is committed to innovation, research and development, establishes multiple research and development platforms, and is constantly developing and improving its medicines to meet the needs of an ever-changing market. The Group is also committed to promoting the development of the industry and promoting pharmaceutical academic knowledge and information through academic promotion projects. The Group has formulated The United Laboratories Methods of Intellectual Property Management to protect its brands and pharmaceutical patents from any infringement. IMPROVING MEDICAL ACCESSIBILITY 15 Environmental, Social and Governance Report 2021 The United Laboratories International Holdings Limited